Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID
AffiliationSouthwest Institute for Research on Women, College of Social and Behavioral Sciences University of Arizona
Family and Community Medicine, College of Medicine, University of Arizona
Center for Rural Health, Mel and Enid Zuckerman College of Public Health, University of Arizona
Comprehensive Pain and Addiction Center, University of Arizona
MetadataShow full item record
PublisherPublic Library of Science
CitationMeyerson, B. E., Bentele, K. G., Russell, D. M., Brady, B. R., Downer, M., Garcia, R. C., Garnett, I., Lutz, R., Mahoney, A., Samorano, S., Arredondo, C., Andres, H. J., Coles, H., & Granillo, B. (2022). Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID. PLoS ONE, 17(10 October).
RightsCopyright © 2022 Meyerson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractObjective To understand patient experience of federal regulatory changes governing methadone and buprenorphine (MOUD) access in Arizona during the COVID-19 pandemic. Methods This community-based participatory and action research study involved one-hour, audiorecorded field interviews conducted with 131 people who used methadone and/or buprenorphine to address opioid use disorder at some point during COVID (January 1, 2020- March 31, 2021) in Arizona. Transcribed data were analyzed using a priori codes focused on federally recommended flexibilities governing MOUD access. Data were quantitated to investigate associations with COVID risk and services access. Results Telehealth was reported by 71.0% of participants, but the majority were required to come to the clinic to attend video appointments with an offsite provider. Risk for severe COVID outcomes was reported by 40.5% of the sample. Thirty-eight percent of the sample and 39.7% of methadone patients were required to be at the clinic daily to get medication and 47.6% were at high risk for COVID severe outcomes. About half (54.2%) of methadone patients indicated that some form of multi-day take home dosing was offered at their clinic, and 45.8% were offered an extra day or two of multi-day doses; but no participants received the federally allowed 14- or 28-day methadone take-home doses for unstable and stable patients respectively. All participants expressed that daily clinic visits interrupted their work and home lives and desired more take-home dosing and home delivery options. Conclusions MOUD patients in Arizona were not offered many of the federally allowed flexibilities for access that were designed to reduce their need to be at the clinic. To understand the impact of these recommended treatment changes in Arizona, and other states where they were not well implemented, federal and state regulators must mandate these changes and support MOUD providers to implement them. © 2022 Meyerson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
NoteOpen access journal
VersionFinal published version
Except where otherwise noted, this item's license is described as Copyright © 2022 Meyerson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.